infinityseek Launches Innovative Omega-3 Solution at BioST 2025 SG

The 5th World Biological Science and Technology Conference 2025 in Singapore has become a platform for groundbreaking advancements in health and biotechnology. On December 17, 2025, the pioneering longevity brand infinityseek unveiled its revolutionary anti-aging solution, capturing the attention of leading researchers and industry experts present at the event.

The conference spotlighted critical research into vascular aging and featured infinityseek’s innovative approach utilizing microalgae-based Omega-3. According to the Global Burden of Cardiovascular Diseases and Risk Factors Report, cardiovascular diseases (CVDs) remain the leading cause of death globally, with 437 million cases of associated disabilities reported in 2023. Current treatments primarily target the later stages of these diseases, leaving significant gaps in addressing the underlying mechanisms of vascular aging.

Infinityseek’s solution aims to fill this void by leveraging natural bio-resources, particularly focusing on the rare microalgae Nannochloropsis. This unique formulation promises to tackle inflammation and lipid metabolism, two critical factors in vascular health. During the presentation, infinityseek’s scientific advisor emphasized the numerous advantages of using Nannochloropsis over traditional Omega-3 sources like fish or krill.

Nannochloropsis, dating back 3.5 billion years, sits at the base of the marine food chain, effectively minimizing the risk of contamination. This ensures that the formulation maintains exceptional purity, which is crucial for consumer safety. Furthermore, its natural polar lipid structure enhances bioavailability, making it 2.2 times more effective than 97% EPA fish oil and leading to a 56% increase in tissue accumulation.

This innovative solution operates through well-defined mechanisms, addressing two primary pathways of vascular aging. The formulation’s abundant Ultra SPMs—third-generation specialized pro-resolving mediators—provide significant anti-inflammatory effects, with preliminary data suggesting marked reductions in key senescence-associated secretory phenotypes (SASPs) within eight weeks. Concurrently, its unique 100% Uni-EPA composition regulates lipid metabolism, achieving targeted lipid-lowering effects within four weeks.

Infinityseek’s commitment to robust scientific research underpins this breakthrough. The brand has established the Longevity Lab and collaborates with renowned institutions such as Lipidomix GmbH from Germany. This partnership allows infinityseek to build a comprehensive scientific framework that spans essential research to product validation. The company’s products have garnered multiple authoritative certifications in China, the United States, and Germany, further affirming their commitment to quality.

“Our core philosophy is grounded in a deep respect for science and a steadfast dedication to long-term, challenging scientific exploration,” said Jains Pang, an R&D expert at infinityseek. “Our objective is to enhance the fundamental understanding of health and deliver truly effective solutions.”

With the formal publication of their research in prestigious international academic platforms, infinityseek aims to advance the understanding of vascular aging interventions. This initiative marks a significant shift in the healthcare industry, highlighting the importance of mechanistic insights and the integration of global scientific knowledge. The development represents a promising new pathway for tackling age-related health challenges on a global scale, potentially transforming the approach to longevity and well-being.